Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.
Smallcaps still overvalued? HDFC Securities’ Unmesh Sharma flags 2 key risks
In this overall, uncertain global environment, India seems better placed. Currently, we are out of the cross hairs from the tariff perspective but need to
March 19, 2025